Collectively, these observations show that IXA4 treatment induced transient and preferential activation of IRE1/XBP1s signaling in the liver, thus offering an opportunity to test the impact of pharmacologic IRE1/XBP1s activation in the context of obesity. Here, ERN1 is linked to obesity disorder.